June 4, 2018 A high dose of a proton-pump inhibitor (PPI) combined with low-dose aspirin reduced the risk of death, esophageal adenocarcinoma (EA), or high-grade dysplasia (HGD) in patients with Barrett’s esophagus (BE) in a long-term, phase III randomized trial. The ASPECT chemoprevention trial results (Abstract LBA4008) were presented during the Gastrointestinal (Noncolorectal) Cancer...
Pro zobrazení tohoto obsahu je třeba být přihlášen.